About
Geert-Jan Mulder, M.D., has served as a member of our board of directors since May 2004. Geert Jan Mulder has been a general partner at Forbion Capital Partners since 2001. Prior to joining ABN AMRO Capital Life Sciences (now Forbion), he was clinical research manager of Byk Gulden (now Takeda) from 1999 to 2001 where his group was responsible for design and execution of early and late-stage clinical trials forming the basis for two global product registrations, Daxas and Alvesco in fields of COPD and asthma. For both products he was a member of the Global Medical Marketing group and supported the line extension program of Pantozol. From 1998 to 1999, he served as medical adviser in the field of arthritis and pain (COX-2 technology) and worked on the local and European positioning of Celebrex at Searle (now Pfizer). In addition to taking an active role in the Forbion Capital Partners investment process, Geert Jan Mulder serves on a number of boards and assists portfolio companies in t
Position in the VCSift Database
- • 29 investors at Forbion Capital Partners are tracked.
- • 1,303 investors hold the Managing Partner role in VCSift. Geert Jan Mulder is one of them.
- • 18 investors are based in Almere, Flevoland, The Netherlands.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Location
- Almere, The Netherlands
Contact Information
Find more investors like Geert
Search Investors